Lumos Pharma, Inc. (LUMO)
| Market Cap | 56.25M |
| Revenue (ttm) | 50,000 |
| Net Income (ttm) | -27.20M |
| Shares Out | 8.36M |
| EPS (ttm) | -3.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,829 |
| Open | 7.10 |
| Previous Close | 7.18 |
| Day's Range | 6.43 - 7.27 |
| 52-Week Range | 6.43 - 22.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 27.17 (+303.7%) |
| Earnings Date | Nov 3, 2021 |
About LUMO
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for Lumos Pharma stock is "Buy." The 12-month stock price forecast is 27.17, which is an increase of 303.71% from the latest price.
News
Down 16.1% in 4 Weeks, Here's Why Lumos (LUMO) Looks Ripe for a Turnaround
Lumos (LUMO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earni...
Lumos Pharma to Participate in Upcoming Investor Conferences
AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will p...
Wall Street Analysts Predict a 190% Upside in Lumos (LUMO): Here's What You Should Know
The mean of analysts' price targets for Lumos (LUMO) points to a 190.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in...
Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates
AUSTIN, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for t...
Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
AUSTIN, Texas, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report it...
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
• Lumos Pharma strengthens leadership team with promotion of John McKew, PhD to President, and addition of David B. Karpf, MD as Chief Medical Officer and Mark Bach, MD, PhD to Advisory Board
Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark...
AUSTIN, Texas, July 26, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach, M.D., P...
Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021
AUSTIN, Texas, July 22, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report it...
Lumos Pharma Delays Data Readout From Pediatric Growth Hormone Deficiency Trial To 2H Of 2023
Lumos Pharma Inc (NASDAQ: LUMO) expects 6-month primary outcome data from Phase 2 OraGrowtH210 Trial of LUM-201 in the 2H of 2023, citing the pace of site initiation and slower than anticipated enrollme...
Lumos Pharma Announces Clinical Updates
AUSTIN, Texas, July 20, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announces an update on clinical a...
Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment
Single-Center Phase 2 Trial to Study the Pharmacokinetics/Pharmacodynamics (PK/PD) and Unique Pulsatile Mechanism of Action of LUM-201 at Two Dose Levels
Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be...
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
AUSTIN, May 05, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the firs...
Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021
AUSTIN, Texas, April 28, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report i...
Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession
Eddie L. Varnado joins Lumos Pharma as Vice President, Finance and Corporate Controller Eddie L. Varnado joins Lumos Pharma as Vice President, Finance and Corporate Controller
Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency
Virtual KOL Event is scheduled for Tuesday, April 27th @ 10:30 AM ET Virtual KOL Event is scheduled for Tuesday, April 27th @ 10:30 AM ET
Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-...
Data show greater GH response in pediatric growth hormone deficiency (PGHD) from LUM-201 than standard GH secretagogues Data show greater GH response in pediatric growth hormone deficiency (PGHD) from L...
3 Net Current Asset Value Stocks
There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they are convinced they can gain from these kinds of investments after the market has reasses...
Lumos Pharma to Participate in March 2021 Investor Conferences
AUSTIN, Texas, March 11, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company is pa...
Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD
AUSTIN, Texas, March 09, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for ...
Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD...
AUSTIN, Texas, March 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, will present poster 7102 at the ...
Will Lumos Pharma (LUMO) Report Negative Earnings Next Week? What You Should Know
Lumos (LUMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lumos Pharma to Report Full Year 2020 Financial Results and Host Conference Call on March 9, 2021
AUSTIN, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report it...
Lumos Pharma Announces Changes to its Board of Directors
Lumos Pharma appoints new Board member, An van Es-Johansson, M.D., with wealth of experience in rare diseases Lumos Pharma appoints new Board member, An van Es-Johansson, M.D., with wealth of experience...
Lumos Pharma (LUMO) in Focus: Stock Moves 8.3% Higher
Lumos Pharma (LUMO) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.